Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PinnacleXon Dec 19, 2019 1:56pm
75 Views
Post# 30473461

RE:RE:RE:RE:RE:RE:estimates 2019

RE:RE:RE:RE:RE:RE:estimates 2019
theo12 wrote: Bad analysts!!!!!!   Another reason once again. Lets stop the if and maybe and let's wait for this and that,  and look at TH's belly button.
The SP is low in spite all the expectations.  Of course, there are no profits.  I am happy the phase 3 will start later than sooner.  Less expenses, and maybe a chance to show some profits,  and then use that tax-free reserve that TH has,  which keeps it from moving to the US, as it is where are the analysts (if we depend on others  to raise the SP).  And why stay in Canada when there are no profits to use those tax-savings?
It is about time that TH shares an outlook to the market and its shareholders, to enable more appropriate investment decisions (forget about the analysts as they are ''bad'').  And this adds to to my reflection on the quality of those who are well paid to run this company,  and hope that they will have the elegancy to not vote themselves more personnal income until duly deserved.   But I am afraid of ''the scratch my back, I'll scratch yours''.


what's more disturbing is the fanboys like wino and speco1 that will vote to give them those options and bonuses you can bet your last dollar on that, because according to them this sh@t bod has done a stellar job.
Bullboard Posts